Affymetrix Deals With Novartis, Cimarron
Affymetrix of the USA has entered into an agreement with Swiss majorNovartis under which the latter will gain access to Affymetrix' GeneChip instrumentation, software and DNA probe arrays to monitor gene expression.
Novartis will have access to standard GeneChip probe arrays that will include certain human and mouse genes, while Affymetrix will receive undisclosed payments determined by the number and nature of genes analyzed. Other major pharmaceutical groups that are currently customers of the GeneChip technology include Hoffmann-La Roche, Glaxo Wellcome and Hoechst Marion Roussel.
Meantime, Affymetrix has signed a licensing agreement with Cimarron Software to incorporate selected portions of the latter's software into the GeneChip instrument.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze